Advertisement

European Journal of Epidemiology

, Volume 25, Issue 1, pp 55–61 | Cite as

Mortality trends in systemic sclerosis in France and USA, 1980–1998: an age-period-cohort analysis

  • Solen Kernéis
  • Pierre-Yves Boëlle
  • Rebecca Freeman Grais
  • Gérard Pavillon
  • Eric Jougla
  • Antoine Flahault
  • Lone Simonsen
  • Thomas Hanslik
Epidemiology of Rheumatic Diseases

Abstract

We compared trends of Systemic Sclerosis (SS) mortality in France and the USA over the period 1980–1998 and used an Age-Period-Cohort (APC) model to adjust on the age at death of SS patients. All deaths coded with SS as an underlying primary or secondary cause in the national French and US mortality databases from 1980 to 1998 were included in the analysis. SS age-standardized mortality rates increased from 7.2 to 10.3/million in US women (+43%), and from 3 to 3.9/million in French women (+22%). Most of the increase occurred in senior women. In contrast, SS age-standardized death rates remained stable among US men (around 3/million) and French men (around 2/million). In US women, the APC analysis shows a growing cohort effect between 1900 and 1940, tending to stabilize for following cohorts. Similar findings were obtained to a lesser extent in French women. In conclusion, SS mortality rates increased by more than 40% between 1980 and 1998 in the USA, mostly in women born between 1900 and 1940. Whether these trends reflect rising incidence of SS need to be documented. The observed dissimilarity between genders and countries underline that environmental exposure and gender-related factors likely play a major etiological role. Stabilization in the following birth cohorts suggests that the increase of mortality observed since 1980 may slow down in the near future.

Keywords

Epidemiology Models, statistical Mortality Scleroderma, systemic Trends 

Abbreviations

AIC

Akaike’s information criterion

APC

Age-period-cohort

Δ Dev

Difference of deviance

INSEE

Institut National de la Statistique et des Etudes Economiques

NCHS

National center for health statistics

SS

Systemic sclerosis

Notes

Acknowledgments

No funding was obtained for this study.

References

  1. 1.
    Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37:223–35.CrossRefPubMedGoogle Scholar
  2. 2.
    Medsger TA Jr, Masi AT. The epidemiology of systemic sclerosis (scleroderma) among male U.S. veterans. J Chronic Dis. 1978;31:73–85.CrossRefPubMedGoogle Scholar
  3. 3.
    Wigley R, Borman B. Medical geography and the aetiology of the rare connective tissue diseases in New Zealand. Soc Sci Med [Med Geogr]. 1980;14:175–83.Google Scholar
  4. 4.
    Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246–55.CrossRefPubMedGoogle Scholar
  5. 5.
    Roberts-Thomson PJ, Jones M, Hakendorf P, et al. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Intern Med J. 2001;31:220–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Le Guern V, Mahr A, Mouthon L, et al. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford). 2004;43:1129–37.CrossRefGoogle Scholar
  7. 7.
    Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum. 2005;34:714–20.CrossRefPubMedGoogle Scholar
  8. 8.
    Allcock RJ, Forrest I, Corris PA, et al. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford). 2004;43:596–602.CrossRefGoogle Scholar
  9. 9.
    Geirsson AJ, Steinsson K, Guthmundsson S, et al. Systemic sclerosis in Iceland. A nationwide epidemiological study. Ann Rheum Dis. 1994;53:502–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Steen VD, Oddis CV, Conte CG, et al. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis Rheum. 1997;40:441–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum. 1997;40:734–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Krishnan E, Furst DE. Systemic sclerosis mortality in the United States: 1979–1998. Eur J Epidemiol. 2005;20:855–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: age-period and age-cohort models. Stat Med. 1987;6:449–67.CrossRefPubMedGoogle Scholar
  14. 14.
    Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: age-period-cohort models. Stat Med. 1987;6:469–81.CrossRefPubMedGoogle Scholar
  15. 15.
    Dobson A. Introduction to generalized linear models. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC; 2001.Google Scholar
  16. 16.
    Au K, Khanna D, Clements PJ, et al. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep. 2009;11:111–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1, 012 Italian patients. Medicine (Baltimore). 2002;81:139–53.CrossRefGoogle Scholar
  18. 18.
    Tan EM, Rodnan GP, Garcia I, et al. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum. 1980;23:617–25.CrossRefPubMedGoogle Scholar
  19. 19.
    Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med. 1997;103:242–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Silman AJ. Mortality from scleroderma in England and Wales 1968–1985. Ann Rheum Dis. 1991;50:95–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Roberts-Thomson PJ, Walker JG, Lu TY, et al. Scleroderma in South Australia: further epidemiological observations supporting a stochastic explanation. Intern Med J. 2006;36:489–97.CrossRefPubMedGoogle Scholar
  22. 22.
    Diot E, Lesire V, Guilmot JL, et al. Systemic sclerosis and occupational risk factors: a case–control study. Occup Environ Med. 2002;59:545–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Gold LS, Ward MH, Dosemeci M, et al. Systemic autoimmune disease mortality and occupational exposures. Arthritis Rheum. 2007;56:3189–201.CrossRefPubMedGoogle Scholar
  24. 24.
    Mayes MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect. 1999;107(Suppl 5):743–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Solen Kernéis
    • 1
    • 2
    • 3
  • Pierre-Yves Boëlle
    • 1
    • 2
  • Rebecca Freeman Grais
    • 1
    • 2
  • Gérard Pavillon
    • 4
  • Eric Jougla
    • 4
  • Antoine Flahault
    • 5
  • Lone Simonsen
    • 6
  • Thomas Hanslik
    • 1
    • 2
    • 3
    • 7
  1. 1.Université Pierre et Marie Curie-Paris6ParisFrance
  2. 2.Faculté de Médecine Pierre et Marie CurieINSERMParis Cedex 12France
  3. 3.Assistance Publique Hôpitaux de Paris (AP-HP)Hôpital Ambroise ParéBoulogne BillancourtFrance
  4. 4.Inserm-CépiDcLe VésinetFrance
  5. 5.French School of Public Health (EHESP)ParisFrance
  6. 6.Department of Global Health, School of Public Health and Health ServicesGeorge Washington UniversityWashingtonUSA
  7. 7.Université Versailles Saint Quentin en YvelinesVersaillesFrance

Personalised recommendations